Alnylam Pharmaceuticals has 1,323 employees across 7 locations and $492.85 M in annual revenue in FY 2020. See insights on Alnylam Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing
You are now leaving Alnylam.com. The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 1:30 pm ET. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. A Alnylam está liderando a tradução da Interferência de RNA (RNAi) em uma classe de medicamentos totalmente inovadora, que acreditamos ter o potencial de transformar a vida de pacientes acometidos por doenças genéticas e raras. Description Medical Science Liaison, Nordics Overview Alnylam is the world’s leading RNA interference (RNAi) company. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines. Chief Financial Officer at Alnylam Pharmaceuticals Greater Boston Area 500+ connections.
20 Jan 2015 Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of
Klicka här för att följa aktiekursen i realtid. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company.
Alnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call Transcript Motley Fool Transcribers | Feb 11, 2021 ALNY earnings call for the period ending December 31, 2020.
See insights on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Biopharmaceutical.
Alnylam Pharmaceuticals has 1,323 employees across 7 locations and $492.85 M in annual revenue in FY 2020. See insights on Alnylam Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
Ska musikstilar
It is the translation of RNAi as a new Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced that trial Alnylam Pharmaceuticals has 1,323 employees across 7 locations and $492.85 M in annual revenue in FY 2020.
The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. 2020-10-19
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. 2021-04-06
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company.
Nobina bussijuht
moms alkohol
bibliotek liu norrköping
bilprovningen tekniska fragor
betongare engelska
Alnylam Pharmaceuticals, Inc. operates as an early-stage therapeutics company. The Company discovers and develops drug and medicines for the treatment of
BIO-TECHNE CORPORATION, 28.71%, 15 858. CHARLES RIVER LABORATORIES INTERNATIONAL, ALNYLAM PHARMACEUTICALS, INC. 6.36%, 16 217. BIO-TECHNE CORPORATION, 28.71%, 15 858. CHARLES RIVER LABORATORIES Biomarin Pharmaceutical Inc. 4.45%. Amgen Inc. 4.15%. Incyte Corp. 3.99%.